Background: COVID-19 has shown a definite association with gender, a predilection for males in terms of morbidity and mortality. The indirect evidence of the protective effect of estrogen has been shown by Channappanavar, in the animal model and Ding T. in a multihospital study from China, suggesting menopause as independent risk factor and estrogen is negatively correlated with severity. Objective: Study the clinical profile and outcomes in premenopausal and menopausal COVID-19-infected women and analyzed the effect of menstrual status on the outcome. Materials and Methods: A retrospective cohort study conducted on 147 mild and moderate category COVID-19 females admitted between May and August 2020 using hospital records and telephonic follow-up. Two groups formed based on menstrual status: group-1 (premenopausal/estrogenic) and Group-2 (menopausal/hypoestrogenic). Hospital stay duration was considered as primary, while the category of disease on admission, clinical course, the requirement of oxygen, and mortality and residual symptoms were taken as a secondary outcome to compare the groups. Results: Overall Group-1 had significantly more of mild disease, while Group-2 had moderate cases (39 [76.5%] vs. 14 [14.6%] \( P < 0.01 \)). Menopausal group has significantly more requirement of oxygen (32 [62.7%] vs. 20 [20.8%]), ventilation (14 [27.5%] vs. 1 [1%]) progression-to-severe disease (23.5% vs. 7.3%) and prolonged hospital stay ([14.1 \pm 8.9 vs. 8.6 \pm 3.9 days] \( P < 0.01 \)). However, multivariate logistic regression failed to show a significant association between hospital stay and progression with menopause. Ferritin and residual symptoms found significantly higher in menopausal. Conclusions: No definite association was found between menopause and COVID-19 outcome with hospital stay duration or disease progression in our study. Keywords: COVID-19, estrogen, menopause, neutrophils/lymphocyte ratio, residual symptoms, World Health Organization Covid-19 category

INTRODUCTION

The outbreak of COVID-19 in China in December 2019 has progressed into a pandemic affecting health infrastructure and economies worldwide.\(^1\) Since then, rigorous research is being carried out to understand its characteristics and outcomes. One of the interesting facts observed about COVID-19 is its definite association with gender in terms of morbidity and mortality. The preponderance of males over females being affected by Severe Acute Respiratory Syndrome– Corona Virus-2 (SARS-Cov-2) has been observed by many studies.\(^2,3\) In China, it was observed that 60% of patients affected by COVID-19 were men.\(^4\) The severity as well as case fatality rate was reported higher in men as compared to women (2.8% vs. 1.7%).\(^2,5\) The reason for this can be drawn from the fact that 17 beta-estradiol
downregulates expressions of angiotensin-converting enzyme-2 (ACE-2) mRNA in epithelial cells that are the primary entry point for the virus inside the host cell as been established by other studies.\(^5,6\)\)

The indirect evidence of the protective effect of estrogen has been shown by Channappanavar et al., in the mice model, demonstrating that female mice administered with estrogen receptor antagonist have higher mortality rate due to SARS-CoV2 when compared with control female mice while this effect was not demonstrated in male mice. They also showed poor prognosis and extensive lung involvement with pro-inflammatory cytokines/chemokines in ovariectomized/gonadectomized female mice.\(^7\)

It is a known fact that pretreatment of human macrophages with the estrogen reduces tumor necrosis factor-\(\alpha\) expression through attenuation of nuclear factor-kappa-\(b\) (NFk-b) activation. Estrogen also attenuates monocyte-macroage recruitment by downregulating chemokine ligand 2 expression among inflammation and dampening toll-like receptors 4-mediated NFk-b activation.\(^8\)\)

In a multicentric study from Wuhan by Ding et al., it was observed that estrogen and anti-Mullerian hormone (AMH) were inversely linked to the severity of COVID-19 with menopause accounting as an independent prognostic variable.\(^9\) However, robust clinical studies are lacking to suggest the true effect of menopause on its presentation and outcomes; hence, this retrospective study was planned to investigate whether menopausal status really affects the COVID-19 disease outcome in women.

**Materials and Methods**

A retrospective cohort study was conducted on COVID-19-infected females admitted between May 2020 and August 2020 at tertiary care dedicated COVID hospital. The data were collected using hospital admission records and telephonic follow-up of eligible women by defined inclusion and exclusion criteria. A COVID-19 confirmed case was defined as a positive result on real-time reverse-transcriptase–polymerase-chain reaction (RT-PCR) assay of nasopharyngeal swab specimens. Permission from the institutional ethics committee was taken to conduct the study.

**Inclusion criteria**

- RTPCR confirmed COVID-19 female patients
- Female 18–70 years of age group
- Women having controlled diabetes/hypertension (HTN)/thyroid or other chronic diseases
- Having mild-to-moderate category disease at the time of admission in both groups.

**Exclusion criteria**

- Pregnant and lactating women
- Asymptomatic women
- Patient with severe category COVID-19 disease at admission
- Currently receiving estrogen-based hormonal therapy
- Having abnormal genital bleeding episodes in the past 3 months
- Subjects already on any cancer therapy
- Women on steroids
- Patients having uncontrolled HTN/diabetes mellitus (DM) or other medical diseases.

Eligible women not giving consent on the telephonic interview, language barrier, and those with incomplete investigation records were also excluded. The overall recruitment pattern is defined in Figure 1.

Data retrieved from hospital medical records included history and examination (general and systemic), COVID-19 disease category (mild/moderate/severe) according to the World Health Organization manual COVID-19.\(^{10}\) Enrolled women were divided into two groups based on menstrual status: group-1 (premenopausal/reproductive age) and Group-2 (menopausal). Premenopausal included those having regular cycles and menopausal having minimum 1 year of amenorrhea.

![Figure 1: Recruitment chart](image-url)
Following investigation profile of enrolled cases were noted; hemogram, liver function tests, renal function tests, electrolytes, prothrombin time, activated partial thrombin time, fibrinogen, inflammatory markers such as C-reactive protein (CRP), ferritin, lactate dehydrogenase (LDH) and d-dimer, chest X-ray, electrocardiogram, and arterial blood gas analysis. Clinical course, biochemical characteristics of the cases over the hospital stay duration, and date of discharge were notified to assess the following outcomes in two of the groups for comparison.

Primary outcomes measure – Hospital stay duration.

Secondary outcome: (1) Change in disease category: progression-to-severe disease. (2) The requirement of oxygen by a simple mask, reservoir mask, high flow nasal cannula (HFNC), noninvasive ventilation (NIV), or mechanical ventilation (3) Mortality.

The discharge criteria were two negative results on RT-PCR assay of nasopharyngeal swab specimens and the patient was advised home quarantine for 14 days. According to the institute’s protocol, all discharged patients were followed up to 8–12 weeks by telemedicine consultation.

In the follow-up, the telephonic interview covered verbal consent, the status of health, gynecological complaints, residual symptoms, and any change in the menstrual pattern since COVID-19 infection in premenopausal women. The correlation of menstrual status with different variables was analyzed using statistical tests.

**Statistical analysis**

Continuous variables were expressed as the means and standard deviations. Categorical variables were summarized as the counts and percentages in each category. A two-tailed *t*-test was applied to continuous variables. Chi-square tests/Fisher’s exact tests were used for categorical variables as appropriate. The univariate logistic regression analysis was done to see the association of length of hospital stay and disease severity with menstruation, age, obesity, comorbidities, oxygen/ventilator requirement, hemoglobin, and neutrophil-to-lymphocyte ratio (NLR). Then, the variables which came out to be significant were put in multivariate logistic regression analysis to see the independent effect of each variable on length of hospital stay and disease severity. All statistical analyses were carried out at 5% level of significance, and *P* < 0.05 was considered significant.

**RESULTS**

The data of a total of 147 COVID-19-positive females were analyzed of which 96 patients belonged to Group-1 (premenopausal), while 51 belonged to Group-2 (menopause) suggesting estrogenic and hypoestrogenic clinical states, respectively.

While evaluating baseline and clinical characteristics, it was found that patients in Group-1 had a mean age of 30.1 ± 8.5 compared to 55.9 ± 10.7 years, and lower body mass index (BMI) (24.5 ± 3.4 vs 29 ± 3.2 kg/m², *P* < 0.01) as compared to Group-2. Overall Group-1 had significantly more number of mild disease cases, while Group-2 had moderate disease (39 [76.5%] vs. 14 [14.6%] *P* < 0.01) and the presence of comorbidities such as DM, HTN, chronic obstructive pulmonary disease (COPD), and cardiac disorders. The thyroid disorders were equally prevalent between both the groups.

Evaluating the clinical course of the disease, it was observed that in Group-1, seven (7.3%) cases progressed toward severe disease, while it was 12 (23.5%) in Group-2 making it statistically significant [Table 1]. The patients in Group-2 had significantly more requirement of oxygen (20 [20.8%] vs. 32 [62.7%], *P* < 0.01) and ventilator (1 [1%] vs. 14 [27.5%], *P* < 0.01). The Group-2 women had prolonged hospital stay also (14.1 ± 8.9 vs. 8.6 ± 3.9 days) *P* < 0.01.

There was no mortality in the premenopausal Group-1, while there were five (9.8%) deaths in the menopausal Group-2. All these five patients had moderate disease at the time of admission, and they progressed rapidly to a critical stage. They all required O₂ supplementation since admission and later required respiratory support in the form of HFNC/NIV/mechanical ventilation. They were managed as per institutes’ protocol with low molecular weight heparin 60 IU subcutaneously twice daily, methylprednisolone, and high-end antibiotics as required. Among these five menopausal women, two were diagnosed cases of COPD, one had valvular heart disease, another was elderly diabetic and one progressed to acute respiratory distress syndrome despite having no comorbidity.

**Biochemical parameters**

The total leukocyte count (TLC) (7800 ± 264.6 vs. 5850 ± 264.6) and neutrophils/lymphocyte ratio (5.2 ± 5.1 vs. 2.6 ± 2.3) was significantly higher (*P* < 0.01) in Group-2 as compared to Group-1. No significant difference was found in mean values of inflammatory markers (CRP, LDH, ferritin, D-dimer) in the two groups; however, in a subset analysis where we compared inflammatory markers between the moderate disease cases in two groups, only ferritin was found significantly higher in the menopausal group [Table 2].
Symptomatology in COVID-19 female patients

Fever and cough were the most common symptoms observed in both groups. The presence of cough, breathlessness, and chest pain were significantly more in Group-2 as compared to Group-1 (72.5% vs. 41.7%; 70.6% vs. 5.2%; 5.9% vs. 0%, $P < 0.01$), respectively. The rest of the symptoms except the loss of taste were more common in Group-2, although statistically not significant. On telemedicine follow-up, 11 women persistently experienced weakness in Group-2 as compared to only four in Group-1 and five women experienced occasional breathlessness compared to none in Group-1; the difference being statistically significant. Overall, 12.5% and 52.2% of patients had residual symptoms in Group-1 and Group-2, respectively. Among Group-1, 12 women experienced oligomenorrhea (infrequent menstrual bleeding), two had menorrhagia (heavy menstrual bleeding), two hypomenorrhea (shortened menstrual bleeding), one each experienced hypo-oligomenorrhea and polymenorrhagia after recovery [Table 3].

The length of hospital stay was categorized into a binomial categorical variable by taking the median number of days (9 days) as the cut off. Univariate logistic regression statistical analysis depicted that menopause status, age, disease progression, presence of any comorbidities, and N/L ratio (cut off = 3.1) were
significantly associated with the hospital stay duration. On putting these variables in a multivariate logistic regression model, the severity of the disease of the study participants was noted to be actually predicting the length of hospital stay. Patients with progressive disease were four times more likely to have a hospital stay of >9 days than those with mild and moderate disease [Table 4].

On univariate logistic regression, menopause status, age, duration of hospital stay, presence of any comorbid conditions, and NLR of the study participants were observed to be significantly associated with the progression of the disease. After using a multivariate logistic regression model, it was noted that only the duration of hospital stay of the study participant actually found associated (P < 0.05) with the severity of disease (AOR = 4.684, confidence interval = 1.155–18.995) [Table 5].

On subgroup analysis, we found more number of affected cases in the late menopause group (38/51; 74.5%) and this group showed more progressive disease (10/12), the requirement of ventilatory support (12/14), and mortality (4/5), although the results were not found statistically significant [Table 6].

**Discussion**

Clinical and biochemical data of a total of 147 women, 51 menopausal and 96 premenopausal, respectively, were collected and 8–12 weeks follow-up information collected telephonically and compared to assess the association of menopausal status and other variables with hospital stay and disease progression. The difference in COVID-19 disease characteristics and afflictions has been notified globally between two genders and the basic difference between male and female physiology is menstruation and sex hormone estrogen.\(^1\)\(^,\)\(^11\)\(^,\)\(^12\) In this study, we tried to find out the impact of menopausal status (hypoestrogenic population) on COVID-19 outcome by comparing clinical profiles with premenopausal normal menstruating women (eu-estrogenic) as the hormonal milieu of both groups is different.

Our study delivered a few interesting findings. Most cases in the menopausal group were in the moderate category at admission (76%) compared to only 14% in the premenopausal group. The menopausal women in our study were overweight (significantly higher BMI) as compared to reproductive-aged females, same as reported by Atapattu.\(^13\)

| Symptoms | Group 1 (n=96), n (%) | Group 2 (n=51), n (%) | P |
|----------|-----------------------|----------------------|---|
| At admission* |                       |                      |   |
| Fever     | 69 (71.9)             | 43 (84.3)            | >0.05 |
| Cough     | 40 (41.7)             | 37 (72.5)            | <0.01 |
| Anosmia   | 10 (10.4)             | 7 (13.7)             | >0.05 |
| Rash      | 1 (1)                 | 0                    | >0.05 |
| Sore throat | 17 (17.7)             | 14 (27.5)            | >0.05 |
| Myalgia   | 8 (8.3)               | 9 (17.6)             | >0.05 |
| GI symptoms | 7 (7.3)              | 7 (13.7)             | >0.05 |
| Sudden onset breathlessness | 5 (5.2)         | 36 (70.6)            | <0.01 |
| Loss of taste | 2 (2.1)              | 0                    | >0.05 |
| Chest pain | 0                    | 3 (5.9)              | <0.01 |
| Weakness  | 2 (2.1)               | 2 (3.9)              | >0.05 |
| **Symptoms** |                       |                      |   |
| Residual symptoms at 8-12 weeks follow-up |           |                      |   |
| Cough     | 3 (3.1)               | 2 (4.3)              | >0.05 |
| Weakness  | 4 (4.1)               | 11 (23.9)            | <0.01 |
| Breathlessness | 0                    | 5 (10.8)            | <0.01 |
| Anosmia   | 3 (3.1)               | 2 (4.3)              | >0.05 |
| Myalgia   | 0                     | 2 (4.3)              | >0.05 |
| Chest pain | 2 (2.1)              | 2 (4.3)              | >0.05 |
| Menstrual pattern changes | 18 (18.75)       | Not applicable | - |
| Oligomenorrhea | 12 (66.6)          |                      |   |
| Hypomenorrhea | 2 (11.1)           |                      |   |
| Oligohypomenorrhea | 1 (5.55)      |                      |   |
| Menorrhagia | 2 (11.1)            |                      |   |
| Polymenorrhagia | 1 (5.55)        |                      |   |

*Symptoms were overlapping among patients. *5 menopausal women were excluded from the analysis (mortality cases). GI: Gastrointestinal
This all might be explained by a combination of advanced age, estrogen depletion, sedentary lifestyle, and higher comorbidities in the menopausal Group-2.

The menopausal women had significantly prolonged hospital stay, almost double 14.1 +8.9 days compared to Group-1 8.6 +3.9 days ($P < 0.01$), progressive disease, and increased requirement of oxygen support. In this study, both groups varied not only in menstrual status (estrogen), but other variables such as age, BMI, comorbidities, along with disease severity at the time of admission. All these variables have its own

| Variables          | Crude’s OR | 95% CI           | P    | Adjusted OR | 95% CI           | P    |
|--------------------|------------|------------------|------|-------------|------------------|------|
|                    | Lower limit| Upper limit      |      | Lower limit  | Upper limit      |      |
| Menopause          |            |                  |      |             |                  |      |
| Yes                | 3.410      | 1.679            | 6.927| 0.001*      | 5.344            | 0.949| 30.090 | 0.057 |
| No                 | Reference  |                  |      | Reference    |                  |      |
| Age group          |            |                  |      |             |                  |      |
| <25                | 0.217      | 0.063            | 0.749| 0.045*      | 0.673            | 0.261| 1.738 | 0.660 |
| 25-40              | 0.202      | 0.063            | 0.672| 0.045*      | 0.351            | 0.056| 2.189 |
| 41-60              | 0.362      | 0.109            | 1.207| 0.426       | 0.042            | 4.372|
| >60                | Reference  |                  |      | Reference    |                  |      |
| Progression of disease |        |                  |      |             |                  |      |
| Severe             | 6.685      | 2.094            | 21.335| 0.001*     | 4.935            | 1.327| 18.352| 0.017*|
| Mild/mod           | Reference  |                  |      | Reference    |                  |      |
| Co-morbidities     |            |                  |      |             |                  |      |
| Yes                | 2.192      | 1.100            | 4.369| 0.026*      | 1.115            | 0.391| 3.185 | 0.838 |
| No                 | Reference  |                  |      | Reference    |                  |      |
| Hemoglobin         |            |                  |      |             |                  |      |
| <11                | 1.746      | 0.852            | 3.579| 0.128       | -                | -    | -     | -     |
| ≥11                | Reference  |                  |      | Reference    |                  |      |
| NLR                |            |                  |      |             |                  |      |
| ≤3.1               | 3.015      | 1.447            | 6.283| 0.003*      | 1.974            | 0.862| 4.520 | 0.198 |
| >3.1               | Reference  |                  |      | Reference    |                  |      |

*Statistically significant. CI: Confidence interval, NLR: Neutrophils/lymphocyte ratio, OR: Odds ratio, CI: Confidence interval

| Table 5: Multivariate logistic regression for predictors of severity of disease |
|-------------------|---------------------------------|-----------------|-----------------|-----------------|-----------------|
| Variables         | Crude’s OR                       | 95% CI          | P               | Adjusted OR     | 95% CI          | P               |
|                   | Lower limit                      | Upper limit     |                 | Lower limit     | Upper limit     |                 |
| Menopause         |                                  |                 |                 |                 |                 |
| Yes               | 3.912                           | 1.432           | 10.690          | 0.008*          | 2.878           | 0.618           | 13.403          | 0.262 |
| No                | Reference                        |                 |                 | Reference       |                 |                 |
| Age groups        |                                  |                 |                 |                 |                 |
| <25               | 0.016                           | 0.003           | 0.095           | 0.015*          | 0.164           | 0.012           | 2.195           | 0.186 |
| 25-40             | 0.157                           | 0.044           | 0.564           | 0.142           | 0.086           | 0.012           | 1.645           | 0.494 |
| 41-60             | 0.148                           | 0.039           | 0.561           | 0.494           | 0.086           | 0.012           | 2.487           | 0.838 |
| ≥60               | Reference                        |                 |                 | Reference       |                 |                 |
| Hospital stay days|                                 |                 |                 |                 |                 |
| ≤9                | 6.685                           | 2.094           | 21.335          | 0.001*          | 4.684           | 1.155           | 18.995          | 0.031* |
| >9                | Reference                        |                 |                 | Reference       |                 |                 |
| Co-morbidities    |                                  |                 |                 |                 |                 |
| Yes               | 6.632                           | 2.231           | 19.709          | 0.001*          | 3.465           | 0.653           | 18.392          | 0.145 |
| No                | Reference                        |                 |                 | Reference       |                 |                 |
| Hemoglobin        |                                  |                 |                 |                 |                 |
| <11               | 3.199                           | 1.196           | 8.555           | 0.021*          | 2.384           | 0.716           | 7.932           | 0.157 |
| ≥11               | Reference                        |                 |                 | Reference       |                 |                 |
| NLR               |                                  |                 |                 |                 |                 |
| ≤3.1              | 7.078                           | 2.476           | 20.231          | <0.001*         | 3.086           | 0.837           | 11.374          | 0.091 |
| >3.1              | Reference                        |                 |                 | Reference       |                 |                 |

*Statistically significant. CI: Confidence interval, NLR: Neutrophils/lymphocyte ratio.
effect on hospital stay duration; therefore, multivariate analysis was tried to overcome such variable bias. Multivariate regression clearly outlined no significant association between menopausal status with hospital stay, controlling age, disease progression, comorbidity, and BMI, while on univariate analysis, it was found significantly associated. Contrary to this Ding et al. from China, has shown menopause as an independent risk factor for the increased hospital stay and for determining the disease severity. They measured female hormones also in 78 women and concluded that estradiol and AMH are negatively correlated with disease severity.\(^9\) We report a significant association between hospital stay and severe disease and vice versa as per multivariate analysis, which has been experienced by Liu et al. too.\(^14\)

In the present study, the mortality rate of postmenopausal women was found higher (five vs. nil; progressing from moderate disease), but the number is too small to comment on significance truly. Cagnacci and Xholli calculated the difference in COVID-19 mortality among men and women according to age and they found favorable prognosis in women which declined after 50–59 years of age. This study points toward the importance of the hormone milieu in women. The hormone, especially estrogen produced by ovaries play a key role in inflammation, immunity, and the expression of ACE receptor, which gets lost after menopause.\(^{10}\) However, Bonaccorsi et al., in another study, stated that menopause per se does not increase the severity of COVID-19 and endorsed that there are no data to suggest to start or withdraw menopause hormone therapy to protect against it.\(^{11}\) Another study by Lee et al. reported nonassociation of gender with mortality and the role of menopausal hormone therapy in improving clinical outcomes.\(^{16}\) The drawback of our study is that we did not assess the estrogen levels and considered estrogenic status clinically based on the presence of regular monthly menstrual cycles in premenopausal Group-1.

Similar to our findings, UK COVID Symptoms Study also concluded that menopause is not linked to hospitalization days, respiratory support, and disease severity significantly as compared to premenopausal women and they attributed poor prognosis in menopausal women to epigenetic age acceleration. They also inferred that combined oral contraceptive intake had a protective effect among premenopausal women, whereas menopausal hormone therapy failed to show any beneficial effects on menopausal women. Since this study is still in preprint, the findings have to be taken with pinch of salt, but at the same time, they cannot be ignored due to its large sample size of 152,637 women.\(^{17}\)

Our study did not find any definite association between menopausal status and disease outcome, as stated by others.\(^9,18\) The reason could be our relatively modest sample size and nonavailability of the value of female hormones. However, we tried to negate that effect by excluding the women with irregular cycles having fluctuating hormone levels. One possible reason may be the good recovery rate of COVID-19 in India.\(^{19}\) The poorer prognosis apparent in COVID-19 in menopausal females might be due to higher age and associate comorbidities.\(^{17}\) The true answer to this question can only be answered by larger future prospective studies or randomized control trials.

### Table 6: Age wise comparison of outcome among menopausal study participants

| Parameters                              | Early menopause | Late menopause | P    |
|-----------------------------------------|-----------------|----------------|------|
| Oxygen requirement, 32/51 (62.7%)       |                 |                |      |
| Yes (n=32)                              | 7 (21.9)        | 14 (43.8)      | 0.294|
| No (n=19)                               | 6 (31.6)        | 7 (36.8)       |      |
| Ventilator requirement, 14/51 (27.5%)  |                 |                |      |
| No (n=37)                               | 11 (29.7)       | 16 (43.2)      | 0.82 |
| Yes (n=14)                              | 2 (14.3)        | 5 (35.7)       |      |
| Progression to disease severity, 12/51 (23.5%) |       |                |      |
| No (n=39)                               | 11 (28.2)       | 13 (33.3)      | 0.424|
| Yes (n=12)                              | 2 (16.7)        | 8 (66.7)       |      |
| Mortality, 5/51 (9.8%)                  |                 |                |      |
| Yes (n=5)                               | 1 (20.0)        | 1 (20.0)       | 0.503|
| No (n=46)                               | 12 (26.1)       | 20 (43.5)      |      |
| Hospital stay mean, 14.1±8.9 days       |                 |                |      |
| ≤9                                      | 7 (35.0)        | 8 (40.0)       | 0.127|
| >9                                      | 6 (19.4)        | 13 (41.9)      |      |

\(^{18}\) The reason could be our relatively modest sample size and nonavailability of the value of female hormones. However, we tried to negate that effect by excluding the women with irregular cycles having fluctuating hormone levels. One possible reason may be the good recovery rate of COVID-19 in India.\(^{19}\) The poorer prognosis apparent in COVID-19 in menopausal females might be due to higher age and associate comorbidities.\(^{17}\) The true answer to this question can only be answered by larger future prospective studies or randomized control trials.
Early menopause, i.e., stage + 1 STRAW +10 last approximately 5–8 years after the final menstrual period, while late menopause, i.e., stage +2 STRAW starts after than when somatic raging (senescence) add over and peripheral fat-based estrone production also is lost. Although clinically apparent, we did not find the statistically significant difference in disease outcome in early versus late menopausal cases or even in >60 years cases in this study. This may be due to a small sample of menopausal group cases. Another hypothesis suggests although the immune-protective effect of estrogen is lost at the same time, the ACE-2 expression is also decreased with age, which reduces the predilection for COVID-19.

**Biochemical parameters**
The TLC, as well as NLR, was observed to be significantly higher in menopausal women (Group-2). Both can be linked to the increased severity of disease in menopausal women, as observed in other studies.[18] Liu et al. observed NLR as an independent predictor for predicting critical illness in COVID-19. They found that patients having NLR >3.13 were predicted to develop critical illness and should be considered for early admission to the intensive care unit (ICU).[20] In a retrospective analysis by Ciccullo et al., also concludes that NLR is useful for early screening for critical illnesses in COVID-19. According to them, NLR <3 was predictive of clinical improvement, while a value >4 was predictive of admission to ICU.[21] Based on these, we also calculated an independent association of NLR with severity adjusting for other factors and did not found such association. We suggest further prospective studies assessing different cut-off values of NLR should be carried out to establish an association between NLR and severe disease.

The other inflammatory markers such as CRP, LDH, D-dimer, and ferritin were observed to be raised in both the groups above the normal values. Mean values of all inflammatory markers found to be much raised in Group-2 (menopausal) compared to Group-1, but no statistical significance could be noted except in subset analysis where ferritin was raised significantly in menopausal patients having the moderate disease [Table 2]. This could again be due to the modest sample size in our study. High values can be due to more number of moderate category disease cases, 76% in Group-2 versus 14.6% in Group-1, but it points out that the immune system is optimally working to cause rise in inflammatory markers in the old menopausal group. Other studies also have found a definite association between disease severity and raised inflammatory markers.[22‑25] This could again be due to the modest sample size in our study.

As per the present study among premenopausal COVID-19 cases, approximately 85% had mild disease, while there were significantly more moderate category cases (76%) in the postmenopausal group. Yu et al. found that though asymptomatic/mild infection could happen at any age, while patients <45 years had a higher chance of being asymptomatic/mild.[26] Fever and cough were the two most common presenting symptoms in both the groups, as observed by other studies.[27,28] We also found that cough, breathlessness (sudden onset), and chest pain were significantly more in the menopausal Group-2. COVID symptom study by Costeira et al. showed more of anorexia, anoxia, hoarse voice, myalgia, and fever in the menopausal group.[17]

After recovery at the time of telephonic follow-up, 12.5% of premenopausal women had residual symptoms (menstrual symptoms excluded) as compared to 52.2% in menopausal women in our study. Similarly, Tenforde et al. also found residual symptoms in 47% of patients above the age of 50 years.[29] Regarding residual symptoms among two groups breathlessness and weakness were found to be significantly more in Group-2 (9.8% vs. 0%; 21.6% vs. 4.1%). It is really difficult to say the persistence of breathlessness is related to menopausal status (hypo-estrogenism) or due to older age or moderate disease status. The menstrual irregularities experienced by premenopausal women could be due to stress of COVID-19 infection or may be due to infection per se we could not find any studies on menstrual pattern post-COVID-19 infection to comment further.

**The strengths of the present study**
1. Strict inclusion and exclusion criteria: patients with irregular cycles and severe disease at the time of admission were excluded
2. Independent effect of menstrual status on COVID-19 clinical outcomes was calculated.

**The limitations of the present study**
1. Retrospective data
2. Modest sample size
3. Hormones levels were not measured.

**Conclusions**
In the earlier studies, estrogen is being given the credit of favorable prognosis among COVID-19 cases based on male preponderance, animal model studies using estrogen antagonists, and human studies measuring estrogen levels, respectively.[7,9,11] Multi-variate logistic regression model suggested that menopausal status independently is not associated with hospital stay duration or progression to the severity in this study,
while stay duration and progressive disease were found independently associated with each other. Although estrogen being steroid theoretically have the immune and inflammation-modulating activity, the pro-coagulant effect cannot be ignored.\cite{30} Therefore, prospective randomized trials are actually required to truly comment on its role and efficacy in managing COVID-19 disease.

**Acknowledgment**

Dr. Mamta Padhy from department of biochemistry.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**REFERENCES**

1. Blumenthal D, Fowler EJ, Abrams M, Collins SR. Covid-19-implications for the health care system. N Engl J Med 2020;383:1483-8.
2. Papadopoulos V, Li L, Samplaski M. Why does COVID-19 kill more elderly men than women? Is there a role for testosterone? Andrology 2020. doi: 10.1111/andr.12688. Epub ahead of print. PMID: 32681716; PMCID: PMC7404939.
3. Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet 2020;395:470-3.
4. Li LQ, Huang T, Wang YQ, Wang ZP, Liang Y, Huang TB, et al. COVID-19 patients’ clinical characteristics, discharge rate, and fatality rate of meta-analysis. J Med Virol 2020;92:577-83.
5. Stelzig KE, Canepa-Escaro F, Schirlo M, Berdnikovs S, Prakash YS, Chiarelli SE. Estrogen regulates the expression of SARS-CoV-2 receptor ACE2 in differentiated airway epithelial cells. Am J Physiol Lung Cell Mol Physiol 2020;318:L1280-1.
6. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020;181:271-80.e8.
7. Channappanavar R, Fett C, Mendiratta K, Ten Eyck PP, Meyerholz DK, Perlman S, et al. Sex-based differences in susceptibility to severe acute respiratory syndrome coronavirus infection. J Immunol 2017;198:4046-53.
8. Murphy AJ, Gryure PM, Pioli PA. Estradiol suppresses NF-kB activation through coordinated regulation of let-7a and miR-125b in primary human macrophages. J Immunol 2010;184:5029-37.
9. Ding T, Zhang J, Wang T, Cui P, Chen Z, Jiang J, et al. Potential Influence of Menstrual Status and Sex Hormones on female SARS-CoV-2 Infection: A Cross-sectional Study from Multicentre in Wuhan, China. Clin Infect Dis 2020. doi: 10.1093/cid/ciaa1022. Epub ahead of print. PMID: 32697835; PMCID: PMC7454316. Available from: https://academic.oup.com/cid/article/doi/10.1093/cid/ciaa1022/5875093.
10. Clinical Management of COVID-19. Available from: https://www.who.int/publications-detail-redirecclinical-management-of-covid-19. [Last accessed on 2020 Oct 16].
11. Cagnacci A, Xholli A. Age-related difference in the rate of coronavirus disease 2019 mortality in women versus men. Am J Obstet Gynecol 2020;223:453-4.
12. Haitao T, Vermunt JV, Abeykoon J, Ghamravi R, Gunaratne M, Jayachandran M, et al. COVID-19 and sex differences: Mechanisms and biomarkers. Mayo Clin Proc 2020;95:2189-203.
13. Atapattu PM. Obesity at Menopause: An Expanding Problem. J Patient Care [Internet] 2015;01(01). Available from: https://www.omicsonline.org/open-access/obesity-at-menopause-an-expanding-problem-ipc-1000103.php?id=66708. [Last cited on 2021 Jan 12]. doi:10.4172/2573-4598.1000103.
14. Liu X, Zhou H, Zhou Y, Wu X, Zhao Y, Lu Y, et al. Risk factors associated with disease severity and length of hospital stay in COVID-19 patients. J Infect 2020;81:e95-7.
15. Bonaccorsi G, Gambacciani M, Gemmati D. Can estrogens protect against COVID-19? The COVID-19 puzzling and gender medicine. Minerva Ginecol 2020;72:178-9.
16. Lee JH, Kim YC, Cho SH, Lee J, You SC, Song YG, et al. Effect of sex hormones on coronavirus disease 2019: An analysis of 5,061 laboratory-confirmed cases in South Korea. Menopause 2020;27:1376-81.
17. Costeira R, Lee KA, Murray B, Christiansen C, Castillo-Fernandez J, Lochlaim MN, et al. Estrogen and COVID-19 symptoms: associations in women from the COVID Symptom Study. medRxiv. 2020.07.30.2016492. Available from: https://doi.org/10.1101/2020.07.30.2016492.
18. Feng X, Li S, Sun Q, Zhu J, Chen B, Xiong M, et al. Immune-inflammatory parameters in COVID-19 cases: A systematic review and meta-analysis. Front Med (Lausanne) 2020;7:301.
19. Revathisree K, Shyam Sudhakar S, Indu R, Srinivaskan K. Covid-19 demographics from a tertiary care center: Does it depreciate quality-of-life? Indian J Otalaryngol Head Neck Surg 2020;1:8.
20. Liu J, Liu Y, Xiang P, Pu L, Xiong H, Li C, et al. Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage. J Transl Med 2020;18:206.
21. Ciccullo A, Borghetti A, Zileri Dal Verme L, Tosoni A, Lombardi F, Garzovich M, et al. Neutrophil-to-lymphocyte ratio and clinical outcome in COVID-19: a report from the Italian front line. Int J Antimicrob Agents 2020;56:106017. Available from: https://doi.org/10.1016/j.ijantimicag.2020.106017. Epub 2020 May 11. PMID: 32437920; PMCID: PMC7211594.
22. Sahu BR, Kampa RK, Padhi A, Panda AK. C-reactive protein: A promising biomarker for poor prognosis in COVID-19 infection. Clin Chim Acta 2020;509:91-4.
23. Yu HH, Qin C, Chen M, Wang W, Tian DS. D-dimer level is associated with the severity of COVID-19. Thromb Res 2020;195:219-25.
24. Vargas-Vargas M, Cortés-Rojo C. Ferritin levels and COVID-19. Rev Panam Salud Publica 2020;44:e72.
25. Han Y, Zhang H, Mu S, Wei W, Jin C, Tong C, et al. Lactate dehydrogenase, an independent risk factor of severe COVID-19 patients: A retrospective and observational study. Aging (Albany NY) 2020;12:11245-58.
26. Yu C, Zhou M, Liu Y, Guo T, Ou C, Yang L, et al. Characteristics of asymptomatic COVID-19 infection and progression: A multicenter, retrospective study. Virulence 2020;11:1006-14.
27. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): A review. JAMA 2020;324:782-93.
28. Pascarella G, Strumia A, Piliego C, Bruno F, Del Buono R, Costa F, et al. COVID-19 diagnosis and management: A comprehensive review. J Intern Med 2020;288:192-206.
29. Tenforde MW, Kim SS, Lindsell CJ, Billig Rose E, Shapiro NI, Files DC, et al. Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a
multistate health care systems network-United States, March-June 2020. MMWR Morb Mortal Wkly Rep 2020;69:993-8.

30. Ramírez I, De la Viuda E, Baquedano L, Coronado P, Llaneza P, Mendoza N, et al. Managing thromboembolic risk with menopausal hormone therapy and hormonal contraception in the COVID-19 pandemic: Recommendations from the Spanish Menopause Society, Sociedad Española de Ginecología y Obstetricia and Sociedad Española de Trombosis y Hemostasia. Maturitas 2020;137:57-62.